Daré Bioscience Launches First-of-Its-Kind Sildenafil Cream, Targets Revenue in 2026
Event summary
- Daré Bioscience began national pre-fulfillment prescriptions for DARE to PLAY™ Sildenafil Cream in February 2026, with revenue expected to start in Q2 2026.
- The company reported $24.7 million in cash and $3.4 million in working capital as of December 31, 2025.
- Daré received $20.8 million in financing proceeds and $20.4 million in non-dilutive funding in 2025.
- Flora Sync LF5, a vaginal probiotic suppository, is expected to launch in Q2 2026.
- Ovaprene, a non-hormonal contraceptive, is in Phase 3 trials with enrollment completion anticipated in 2026.
The big picture
Daré Bioscience is positioning itself as a leader in women's health innovation, addressing unmet needs with a portfolio of products targeting sexual health, contraception, and vaginal microbiome balance. The company's dual-path strategy of leveraging 503B compounding while pursuing FDA approvals reflects a broader industry trend of balancing rapid market access with long-term regulatory validation. With multiple near-term catalysts, Daré's ability to execute across its pipeline will be critical in sustaining investor confidence and market differentiation.
What we're watching
- Revenue Diversification
- The pace at which Daré can scale revenue from multiple products, including DARE to PLAY and Flora Sync LF5, will determine its financial stability.
- Regulatory Pathways
- Whether Daré can successfully navigate the 505(b)(2) NDA pathway for its sildenafil cream while maintaining its 503B compounded product strategy.
- Clinical Trial Success
- The outcome of Ovaprene's Phase 3 trial and the potential for partnership opportunities based on the data.
Related topics